Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial.
复制标题
DOI：
10.1016/j.ygyno.2013.02.023
复制
发表时间：
2013-05
影响因子：
4.7
通讯作者：
Zaino R
中科院分区：
文献类型：
--
作者：
Brinton LA;Felix AS;McMeekin DS;Creasman WT;Sherman ME;Mutch D;Cohn DE;Walker JL;Moore RG;Downs LS;Soslow RA;Zaino R
Although the epidemiology of typical endometrial carcinomas (grades 1–2 endometrioid or Type I) is well established, less is known regarding higher grade endometrioid or non-endometrioid carcinomas (Type II). Within a large Gynecologic Oncology Group trial (GOG-210), which included central pathology review, we investigated the etiologic heterogeneity of endometrial cancers by comparing risk factors for different histologic categories. Based on epidemiologic questionnaire data, risk factor associations, expressed as odds ratios (OR) with 95% confidence intervals (CI), were estimated comparing grade 3 endometrioid and Type II cancers (including histologic subtypes) to grades 1–2 endometrioid cancers. Compared with 2,244 grades 1–2 endometrioid cancers, women with Type II cancers (321 serous, 141 carcinosarcomas, 77 clear cell, 42 mixed epithelial with serous or clear cell components) were older; more often non-white, multiparous, current smokers; and less often obese. Risk factors for grade 3 endometrioid carcinomas (n=354) were generally similar to those identified for Type II cancers, although patients with grade 3 endometrioid tumors more often had histories of breast cancer without tamoxifen exposure while those with Type II tumors were more frequently treated with tamoxifen. Patients with serous cancers and carcinosarcomas more frequently had breast cancer histories with tamoxifen treatment compared to patients with other tumors. Risk factors for aggressive endometrial cancers, including grade 3 endometrioid and non-endometrioid tumors, appear to differ from lower grade endometrioid carcinomas. Our findings support etiologic differences between Type I and II endometrial cancers as well as additional heterogeneity within Type II cancers.
登录
查看更多内容
影响因子：
3.8
作者：
Lacey, JV;Brinton, LA;Schairer, C
通讯作者：
Schairer, C
影响因子：
6.9
作者：
McTiernan, Anne;Wu, LieLing;Wang, C. Y.
通讯作者：
Wang, C. Y.
影响因子：
4.7
作者：
Gehrig, PA;Bae-Jump, VL;Van Le, L
通讯作者：
Van Le, L
DOI：
10.1111/igc.0b013e3181cd242f
发表时间：
2010-12-01
影响因子：
4.8
作者：
Lavie, Ofer;Ben-Arie, Alon;Gemer, Ofer
通讯作者：
Gemer, Ofer
DOI：
10.1158/1055-9965.epi-10-0742
发表时间：
2010-11
期刊：
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
影响因子：
--
作者：
Martínez ME;Cruz GI;Brewster AM;Bondy ML;Thompson PA
通讯作者：
Thompson PA